GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Cash-to-Debt

Cardiff Oncology (STU:XE7C) Cash-to-Debt : 34.81 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cardiff Oncology's cash to debt ratio for the quarter that ended in Dec. 2023 was 34.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cardiff Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cardiff Oncology's Cash-to-Debt or its related term are showing as below:

STU:XE7C' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.83   Med: 20.5   Max: No Debt
Current: 34.82

During the past 13 years, Cardiff Oncology's highest Cash to Debt Ratio was No Debt. The lowest was 1.83. And the median was 20.50.

STU:XE7C's Cash-to-Debt is ranked better than
69.68% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs STU:XE7C: 34.82

Cardiff Oncology Cash-to-Debt Historical Data

The historical data trend for Cardiff Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cardiff Oncology Cash-to-Debt Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.91 150.79 45.14 38.77 34.81

Cardiff Oncology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.77 37.63 36.72 35.44 34.81

Competitive Comparison of Cardiff Oncology's Cash-to-Debt

For the Biotechnology subindustry, Cardiff Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cash-to-Debt falls into.



Cardiff Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cardiff Oncology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cardiff Oncology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology  (STU:XE7C) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Cardiff Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines